enGene Holdings Inc.
ENGNHealthcare|Biotechnology|CA
$1.75
+0.07 (+4.17%)
DCF Value
$0.28
Tangible Book / Share
$3.30
Cash / Share
$3.82
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04752722 LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | P1P2 | Recruiting | 350 | Open-label | EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) |